Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 109 participants.

Also called NCT06448962

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 109 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06448962
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06448962. Randomized; double masking; primary purpose treatment. Start 2020-10-22 (actual); primary completion 2021-11-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
Condition
Hypertension, Essential
Condition
Primary Hypercholesterolemia
Intervention (Drug)
AD-2021
Intervention (Drug)
AD-2022
Intervention (Drug)
AD-2021 Placebo
Intervention (Drug)
AD-2022 Placebo
Lead sponsor
Addpharma Inc. (class: industry)

Record details

Record id
cardio:ct-nct06448962
Content hash
4dca2a4a453c17670f84865bdeb6dca1c165b88ca8e9df8710119d34503a088b